From the study: “Cannabigerol (CBG) is a phytocannabinoid increasing in popularity, with preclinical research indicating it has anxiolytic and antidepressant effects. Relative to placebo, there was a significant main effect of CBG on overall reductions in anxiety as well as reductions in stress at T1. CBG also enhanced verbal memory relative to placebo. There was no evidence of subjective drug effects or impairment. CBG may represent a novel option to reduce stress and anxiety in healthy adults.”
The non-psychoactive cannabinoid cannabidiol (CBD) effectively inhibits the growth of different types of tumors in vitro and in vivo and down-regulates some pro-angiogenic signals produced by glioma cells. As its anti-angiogenic properties have not been thoroughly investigated to date, and given its very favorable pharmacological and toxicological profile, here, we evaluated the ability of CBD to modulate tumor angiogenesis…”
The results were submitted to a repeated-measures analysis of variance. Pretreatment with CBD significantly reduced anxiety, cognitive impairment and discomfort in their speech performance, and significantly decreased alert in their anticipatory speech. The placebo group presented higher anxiety, cognitive impairment, discomfort, and alert levels when compared with the control group as assessed with the VAMS…”
Cannabidiol (CBD) is an active cannabinoid found in cannabis which, unlike THC (tetrahydrocannabinol), does not produce a psychoactive effect in the brain. For this reason, CBD has become a primary focus of medicinal cannabis studies.